ArticleNature communications2023
Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 39 citations in OpenAlex.
- Identification of cancer-associated fibroblast biomarkers in cutaneous squamous cell carcinoma.Oncology letters · 2026Article
- Role of the circadian rhythm in squamous cell carcinoma: From molecular mechanism to therapy (Review).Molecular medicine reports · 2026Review
- The Evolving Landscape of Actinic Keratosis: Field Therapy, New Drugs, and Future Directions.American journal of clinical dermatology · 2026Review
- Comprehensive molecular characterization of cutaneous squamous cell carcinoma reveals determinants of metastatic progression.medRxiv : the preprint server for health sciences · 2026Article
- Oncogenic Ras drives EED degradation and PRC2 dysfunction to promote aggressive squamous cell carcinoma.Nature communications · 2026Article
- Article
- Protocol for inducing cutaneous squamous cell carcinoma with chronic UV and treating with 5-aminolevulinic acid photodynamic therapy in SKH-1 mice.STAR protocols · 2026Article
- CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.Cell death & disease · 2026Article
- Single-Cell Transcriptomic Mapping of PD-L1/TLR4 Remodeling Informs Topical Immunoprevention Timing in Skin Carcinogenesis.bioRxiv : the preprint server for biology · 2026Article
- PHF20 stabilizes the GAS7-F-actin axis to drive DNA damage repair and chemoresistance in cutaneous squamous cell carcinoma.Cell death & disease · 2026Article
- Epidermal PPARγ Signaling as a Suppressor of Toll-like Receptor-Mediated Inflammation and Fibrosis: Relevance to Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
- Lactylome Reprogramming Mediates Therapeutic Response and Adaptation to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.Molecular & cellular proteomics : MCP · 2026Article
- An estrogen receptor/E2F1/CDKN3 axis protects from UV-induced skin cancers in females.EMBO reports · 2026Article
- The Dutch cutaneous squamous cell carcinoma and metastasis (D-SQUAME) study: a nationwide discovery cohort and nationwide validation cohort with nested case-control designs for risk prediction modeling.European journal of epidemiology · 2026Article
- Superior Induction of Apoptosis by Blue Light Compared to Red Light Photodynamic Therapy in Cutaneous Squamous Cell Carcinoma Keratinocytes.Journal of biophotonics · 2026Article
- Genomic Insights into Cutaneous Squamous Cell Carcinoma.Cancers · 2026Article
- Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Article
- The dynamics of mutational selection in cutaneous squamous carcinogenesis.Communications biology · 2026Article
- SOX2 confers tumour permissiveness in a specific skin progenitor population.Nature communications · 2026Article
- In Vivo CRISPR Interference Screen Reveals Long Noncoding RNA Portfolio Crucial for Cutaneous Squamous Cell Carcinoma Tumor Growth.The Journal of investigative dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 10 institutions in 4 countries.
Funding
Abstract
The molecular basis of disease progression from UV-induced precancerous actinic keratosis (AK) to malignant invasive cutaneous squamous cell carcinoma (cSCC) and potentially lethal metastatic disease remains unclear. DNA sequencing studies have revealed a massive mutational burden but have yet to illuminate mechanisms of disease progression. Here we perform RNAseq transcriptomic profiling of 110 patient samples representing normal sun-exposed skin, AK, primary and metastatic cSCC and reveal a disease continuum from a differentiated to a progenitor-like state. This is accompanied by the orchestrated suppression of master regulators of epidermal differentiation, dynamic modulation of the epidermal differentiation complex, remodelling of the immune landscape and an increase in the preponderance of tumour specific keratinocytes. Comparative systems analysis of human cSCC coupled with the generation of genetically engineered murine models reveal that combinatorial sequential inactivation of the tumour suppressor genes Tgfbr2, Trp53, and Notch1 coupled with activation of Ras signalling progressively drives cSCC progression along a differentiated to progenitor axis. Taken together we provide a comprehensive map of the cSCC disease continuum and reveal potentially actionable events that promote and accompany disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.